

May 25, 2026

To whom it may concern:

Name of company: Nippon Kayaku Co., Ltd.  
Name of representative: Shigeyuki Kawamura, President  
Code No.: 4272  
Tokyo Stock Exchange, Prime Market  
Contact: Masako Aono, Senior Director  
Corporate Communications Division  
TEL: +81-3-6731-5237

**Nippon Kayaku Concludes Agreement for Succession of Marketing Approval for Zoladex®  
3.6mg Depot / LA 10.8mg Depot**

Nippon Kayaku Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO: Shigeyuki Kawamura; hereinafter "Nippon Kayaku") is pleased to announce that it has concluded an agreement (hereinafter "the Agreement") with AstraZeneca K.K. (Head Office: Osaka-shi, Osaka; President and Representative Director: Andrew Barnett; hereinafter "AstraZeneca") regarding the succession of marketing approval in Japan for Zoladex® 3.6mg depot / LA 10.8mg depot (hereinafter "the Product"), which is currently manufactured and marketed by AstraZeneca.

Based on this Agreement, Nippon Kayaku, which has a wealth of experience and a solid foundation in the oncology field, will succeed the Product. By doing so, we aim to optimize the Product's lifecycle and strive to maintain and secure a stable and long-term supply system.

We will announce the effective date of the succession of marketing approval based on this Agreement once it has been determined.

The succession of the Product has already been incorporated into the full-year (fiscal year ending March 2027) earnings forecast announced on May 12, 2026, as an outlook based on the expected conclusion of the agreement. Therefore, the succession mentioned in this release will not affect this fiscal year's earnings forecast. Furthermore, if a long-term impact is anticipated due to future contract performance, market trends, etc., we will disclose it separately and in a timely manner.

[For inquiries regarding this matter]  
Corporate Communications Division, Nippon Kayaku Co., Ltd.  
TEL: +81-3-6731-5237